MOREPEN LABORATORIES LTD. - 500288 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith letter dated 17th November, 2021, received from Registrar and Share Transfer Agent (viz., Mas Services Limited) of the company regarding loss of share certificates of the company. Morepen Laboratories Ltd - 500288 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith letter dated 12th November, 2021, received from Registrar and Share Transfer Agent (viz., Mas Services Limited) of the company, comprising information related to issue of duplicate share certificates of the company.
MOREPEN LABORATORIES LTD. - 500288 - Statement Of Deviation Or Variation In Utilization Of Funds Raised Pursuant To Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please note that there is no deviation or variation in utilization of funds raised, in the quarter ended September 30, 2021. Please find enclosed nil statement of deviation or variation in this regard.
Morepen Labs Q2 net profit up 38% to Rs 37 crore
The company had posted a net profit of Rs 27.16 crore for the corresponding period of the previous fiscal, Morepen Laboratories said in a regulatory filing. Q2FY22 Quarterly Result Announced for Morepen Laboratories Ltd.
Highlights: Q2 FY22 Revenue at Rs. 398 crores jump by 17% against Q2’FY21 revenues of Rs. 340 crores Profit Before Tax at Rs. 46.86 crores UP by 70% Net Profit After Tax at Rs. 37.36 crores UP by 38% Earnings per Share (EPS) - Basic for Q2 at Rs. 0.83 UP by 38% Domestic Revenues at Rs. 276.40 crores are UP by 30%. API Business made largest Revenue contribution of Rs. 201 crores to Q2 Revenues. Medical Devices Revenues for Q2 at Rs. 122.59 crores grew by 36% Quarter on Quarter basis Medical Devices Business is being placed in a separate wholly owned subsidiary. EBITDA for Q2 FY22 at Rs. 44.88 crores is up by 26 percent YoY basis whereas Cash Profit (Before Tax) at Rs. 54.00 crores is up by 53 percent in the same period. Profit margin before tax has leaped by 368 bps from 8.09 percent to 11.77 percent in Q2 FY22 as against Q2 FY21 Mr. Sushil Suri, Chairman and Managing Director stated, “With massive increase in API demand globally and more particularly with frequent supply disruptions from China, we are putting our expansion plans for API on fast track. We have planned to treble the API capacity from present 310 KL to 1000KL in the coming 24 months at the same site in Baddi (HP) within the same plant and at the additional land adjoining the site for which all approvals are in place. We are very bullish on this expansion to capture this large spurt in demand APIs globally. The new capacities are also required to serve the new generic market opening up in the next 5-7 years” Result PDF MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investors Presentation (Q2' FY22) November, 2021 Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release - 'Morepen records 70 percent increase in Profit before tax in Q2 Consolidated Revenue grows by 17%' Morepen Laboratories Ltd - 500288 - Results-Financial Results For Quarter And Half Year Ended September 30, 2021
This is to inform you that the Board of Directors of the Company, in their meeting held on Thursday, 11th November, 2021 (commenced at 11.00 A.M. and concluded at 01.30 P.M.), have, inter-alia, considered and approved the unaudited standalone and consolidated financial results of the company for the quarter and half year ended 30th September, 2021, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A copy of the 'Results' along-with the 'Limited Review Report' of the Auditors of the Company for the quarter and half year ended 30th September, 2021 is enclosed herewith. MOREPEN LABORATORIES LTD. - 500288 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company Held On November 11, 2021
This is to inform you that the Board of Directors of the Company, in their meeting held on Thursday, 11th November, 2021 (commenced at 11.00 A.M. and concluded at 01.30 P.M.), have, inter-alia, considered and approved the unaudited standalone and consolidated financial results of the company for the quarter and half year ended 30th September, 2021, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A copy of the 'Results' along-with the 'Limited Review Report' of the Auditors of the Company for the quarter and half year ended 30th September, 2021 is enclosed herewith.